Drug Profile
AL 611
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Alios BioPharma
- Class Antivirals
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for phase-I development in Hepatitis-C in Belgium (PO, Tablet)
- 25 Oct 2017 Alios Biopharma terminates a phase I trial in Hepatitis C in Belgium as a strategic decision to discontinue further development of investigational drugs for the treatment of hepatitis C (NCT03253471)
- 07 Jul 2017 Phase-I clinical trials in Hepatitis C in Belgium (PO) (NCT03253471)